Literature DB >> 20850637

A case of renal cell carcinoma after successful treatment of Wilms tumor.

Barrie S Rich1, Maureen P McEvoy, Michael P La Quaglia.   

Abstract

This case report documents the eighth reported case of renal cell carcinoma (RCC) occurring after treatment of Wilms tumor. Although secondary malignancies after treatment of Wilms tumors are not infrequent, RCC as the second malignancy is rare. We discuss a 17-year-old girl whose RCC was diagnosed 12.5 years after diagnosis of a Wilms tumor. In addition, we review the literature on the subject. Renal cell carcinoma has been proposed as a consequent of chemoradiation; however, a genetic susceptibility must be considered. Because it is routine to assess the functional status of the remaining solitary kidney by annual ultrasonography, we recommend assessing for the presence of secondary renal malignancies and perhaps continuing routine ultrasounds long-term.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20850637     DOI: 10.1016/j.jpedsurg.2010.06.032

Source DB:  PubMed          Journal:  J Pediatr Surg        ISSN: 0022-3468            Impact factor:   2.545


  3 in total

Review 1.  Urological issues arising after treatment of pediatric malignancies.

Authors:  Rodrigo L P Romao; Ashley Cox
Journal:  Can Urol Assoc J       Date:  2018-04       Impact factor: 1.862

Review 2.  Innovations in the management of Wilms' tumor.

Authors:  Joseph M Gleason; Armando J Lorenzo; Paul R Bowlin; Martin A Koyle
Journal:  Ther Adv Urol       Date:  2014-08

3.  Secondary renal neoplasia following chemotherapy or radiation in pediatric patients.

Authors:  Sounak Gupta; Chad M Vanderbilt; Bradley C Leibovich; Loren Herrera-Hernandez; Aditya Raghunathan; William R Sukov; Jesse S Voss; Emily G Barr Fritcher; Katelyn A Reed; Christine M Lohse; Victor E Reuter; Rafael E Jimenez; R Houston Thompson; John C Cheville
Journal:  Hum Pathol       Date:  2020-07-15       Impact factor: 3.466

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.